Lexeo Therapeutics SEC filings
Filter: All · 8-K · 10-Q · 10-K · Form 4
Results of operations and financial condition · Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedLexeo Therapeutics Q3 2026 net loss of $0.43 per share misses $0.32 consensus, while LX2020 interim data show 80% NSVT reduction
Completion of acquisition or disposition of assets · Unregistered sales of equity securities · Financial statements and exhibits
Entry into a material definitive agreement · Other events · Financial statements and exhibits
Results of operations and financial condition · Other events · Financial statements and exhibits